KMTS

Kestra Medical Technologies, Ltd. Common Stock (KMTS) SWOT Analysis Analysis (2026)

Invetso Score: 3.9/10 — Weak · Last Updated: 2026-08-01

Strengths

Negative cash conversion cycle of -106.6 days indicates KMTS collects cash before paying suppliers, supporting working-capital efficiency versus peers with longer cycles.

Net debt to EBITDA of 0.40x and debt-to-equity of 0.18x suggest a conservative balance sheet, leaving more financial flexibility than more levered peers.

Weaknesses

ROIC of -43.7% signals value destruction and materially weaker capital efficiency than profitable peers, limiting KMTS's structural positioning over a full cycle.

The absence of reported operating and gross margins reduces transparency versus peers, but the negative ROIC still implies weak underlying profitability.

Very high current and quick ratios above 4.2x indicate excess liquidity relative to peers, which can reflect underutilized capital rather than superior operating strength.

Opportunities

If KMTS converts its strong working-capital profile into sustained earnings, peers with weaker cash discipline would face a relative disadvantage in funding growth.

Low leverage creates room to absorb volatility or fund operational improvements more easily than indebted peers, supporting future competitive resilience.

The lack of disclosed segment concentration metrics leaves open the possibility of diversification benefits that could compare favorably with more concentrated peers.

Threats

Persistent negative ROIC versus peers threatens long-term competitiveness because capital deployed into the business is not yet generating adequate returns.

Peers with stronger margins and positive returns can compound faster, widening the gap in scale, reinvestment capacity, and market positioning.

Excess liquidity may mask weak demand or limited reinvestment opportunities, leaving KMTS vulnerable if peers deploy capital more productively.

Overall Score

KMTS shows balance-sheet and working-capital resilience, but deeply negative ROIC and limited profitability evidence leave its structural positioning weaker than stronger peer operators.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Kestra Medical Technologies, Ltd. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →